Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Non Operating Income (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Non Operating Income for 10 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 167.67% year-over-year to $3.4 million, compared with a TTM value of $149.6 million through Dec 2025, up 4869.56%, and an annual FY2025 reading of $149.6 million, up 4869.56% over the prior year.
  • Non Operating Income was $3.4 million for Q4 2025 at Zevra Therapeutics, up from -$5.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $147.9 million in Q2 2025 and bottomed at -$17.3 million in Q1 2021.
  • Average Non Operating Income over 5 years is $7.4 million, with a median of $271500.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 22595.65% in 2023, while the deepest fall reached 5333.33% in 2023.
  • Year by year, Non Operating Income stood at $173000.0 in 2021, then surged by 9022.54% to $15.8 million in 2022, then plummeted by 130.0% to -$4.7 million in 2023, then dropped by 4.58% to -$5.0 million in 2024, then skyrocketed by 167.67% to $3.4 million in 2025.
  • Business Quant data shows Non Operating Income for ZVRA at $3.4 million in Q4 2025, -$5.1 million in Q3 2025, and $147.9 million in Q2 2025.